CompletedPhase 2NCT00003635
506U78 in Treating Patients With Chronic Lymphocytic Leukemia That Has Not Responded to Fludarabine or Alkylating Agents
Studying Aggressive NK-cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- GlaxoSmithKline
- Principal Investigator
- Tonya M. Peele, MSGlaxoSmithKline
- Intervention
- nelarabine(drug)
- Eligibility
- 18 years · All sexes
- Timeline
- 1999 – 2004
Study locations (22)
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama, United States
- Arizona Cancer Center, Tucson, Arizona, United States
- University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
- Scripps Clinic, La Jolla, California, United States
- Cedars-Sinai Medical Center, Los Angeles, California, United States
- Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
- Sidney Kimmel Cancer Center, San Diego, California, United States
- Clinical Studies, Ltd., Denver, Colorado, United States
- Lombardi Cancer Center, Washington D.C., District of Columbia, United States
- Walter Reed Army Medical Center, Washington D.C., District of Columbia, United States
- Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois, United States
- University of Chicago Cancer Research Center, Chicago, Illinois, United States
- Holden Comprehensive Cancer Center at The University of Iowa, Iowa City, Iowa, United States
- Johns Hopkins Oncology Center, Baltimore, Maryland, United States
- Medicine Branch, Bethesda, Maryland, United States
- +7 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00003635 on ClinicalTrials.govOther trials for Aggressive NK-cell leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06716658JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell LymphomasInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT05863234Safety Evaluation Study for Patients With Aggressive NK-cell LeukemiaHiroshima University Hospital
- RECRUITINGPHASE2NCT05941156Clinical Study of Anti-CD56-CAR-T in the Treatment of Relapsed/Refractory NK/T Cell Lymphoma /NK Cell LeukemiaThe Affiliated Hospital of Xuzhou Medical University